Novel non-sulfonamide 5-HT 6 receptor partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties

A small library of novel 3H-imidazo[4,5-b]pyridine and 1H-imidazo[4,5-c]pyridine derivatives was designed and synthesized as non-sulfonamide 5-HT receptor ligands. In vitro evaluation allowed to identify compound 17 (2-ethyl-3-(3-fluorobenzyl)-7-(piperazin-1-yl)-3H-imidazo[4,5-b]pyridine) as potent...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2018-01, Vol.144, p.716-729
Main Authors: Vanda, David, Soural, Miroslav, Canale, Vittorio, Chaumont-Dubel, Séverine, Satała, Grzegorz, Kos, Tomasz, Funk, Petr, Fülöpová, Veronika, Lemrová, Barbora, Koczurkiewicz, Paulina, Pękala, Elżbieta, Bojarski, Andrzej J, Popik, Piotr, Marin, Philippe, Zajdel, Paweł
Format: Article
Language:English
Subjects:
Chemical Sciences
Life Sciences
Medicinal Chemistry
Neurons and Cognition
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A small library of novel 3H-imidazo[4,5-b]pyridine and 1H-imidazo[4,5-c]pyridine derivatives was designed and synthesized as non-sulfonamide 5-HT receptor ligands. In vitro evaluation allowed to identify compound 17 (2-ethyl-3-(3-fluorobenzyl)-7-(piperazin-1-yl)-3H-imidazo[4,5-b]pyridine) as potent 5-HT receptor partial inverse agonist in G signaling (K  = 6 nM, IC  = 17.6 nM). Compound 17 displayed high metabolic stability, favorable cytochrome P450 isoenzyme (2D6, 3A4) profile, did not affect PgP-protein binding, without evoking mutagenic effects. It was orally bioavailable and brain penetrant. In contrast to intepirdine (SB-742457), which prevented 5-HT R-elicited neurite growth and behaved as an inverse agonist of cyclin-dependent kinase 5 (Cdk5), compound 17 has no influence on neuronal differentiation. Compound 17 exerted significant pro-cognitive properties in novel object recognition (NOR) task in rats reversing both phencyclidine- and scopolamine-induced memory deficits (MED = 1 and 0.3 mg/kg, p.o, respectively). These effects were similar to those produced by intepirdine. Additionally, combination of inactive doses of compound 17 (0.1 mg/kg) and donepezil (0.3 mg/kg) produced synergistic effect to reverse scopolamine-induced memory deficits. Accordingly, investigating putative divergence between inverse agonists and neutral antagonists as cognitive enhancers in neurodegenerative and psychiatric disorders is certainly of utmost interest.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2017.12.053